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EFV is a non-nucleoside reverse transcriptase inhibitor and is used as part of the
highly active antiretroviral therapy for the treatment of human immunodeficiency virus
type 1 (HIV) infection. It is also used in combination with other antiretroviral agents as
part of an expanded post-exposure prophylaxis regimen to prevent HIV transmission
for those exposed to materials associated with a high risk of HIV transmission.
EFV has poor aqueous solubility and is a BCS class II drug (1). EFV tablets of 600
mg are available, while lower doses (50, 100 and 200 mg) are generally available as cap-
sules and are prepared by a wet granulation process (2, 3).
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Efavirenz (EFV) tablets of different doses were prepared
by a wet granulation process using different superdisin-
tegrants such as crosscarmellose sodium (CCS), sodium
starch glycollate (SSG) and crosspovidone (CP) to evalu-
ate the role of different disintegrants on the in vitro relea-
se of EFV. Further, the mode of addition of disintegrants
on EFV dissolution from tablets containing 600 mg of the
drug was evaluated by incorporating the disintegrants
extragranularly (EG), intragranularly (IG) or distributing
them equally (IG and EG). In vitro dissolution of the pre-
pared tablets was conducted using the recommended
medium and a dissolution medium developed in-house,
which had the ability to discriminate between the for-
mulations.
The t50 and t80 values were indicative of the fact that the
drug release was faster from tablet formulations contain-
ing CP. CP was able to release the drug faster than the
other two disintegrants in both dissolution media and
the drug release was unaffected by the mode of CP addi-
tion.
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Superdisintegrants generally improve disintegration efficiency compared to tradi-
tional disintegrants. They are generally used at low levels in solid dosage forms, typi-
cally 1–10 % of mass relative to the total mass of the dosage unit (4). Examples of super-
disintegrants are crosscarmellose sodium (CCS), sodium starch glycollate (SSG) and
crosspovidone (CP), which are cross-linked cellulose, a cross-linked starch and a cross-
-linked polymer (polyvinyl pyrrolidone), respectively. Wet granulation is one of the fre-
quently used techniques to prepare blends to be compressed into tablets. The disinte-
grant can be incorporated in the blend before granulation, referred to as intragranular
addition (IG), or after granulation, referred to as extragranular addition (EG), or it can
be distributed both intra and extragranularly.
EXPERIMENTAL
Materials
Efavirenz (Aurbindo Pharma Ltd., India) was purchased from the source indicated.
Crosscarmellose sodium (Ac-di-sol®, FMC biopolymer) and SSG (Glycol YS®, Roquette)
were purchased from Signet (India). Polyvinyl pyrrolidone (PVP-Plasdone K29/32),
Crosspovidone (Polyplasdone XL-10) were from ISP India Pvt Ltd., India. MCC PH 101,
lactose, magnesium stearate and Aerosil were purchased from Signet (India). All other
reagents used were of analytical grade.
Methods
Preparation of granules. – Weighed amounts of the drug, diluent, IG superdisinteg-
rant (if required by experimental design) and binder were passed through 0.595 mm sie-
ve and pre-mixed in the granulator jar (4M-8 high shear granulator, Pro-C-Ept, Belgium)
at impeller speed ranging from 1000–1200 rpm for 60 seconds. Water (8–10 % of batch
size) was added at a pre-determined rate after 120 seconds, the chopper was started
(2300–2500 rpm) and granulation proceeded for 10 minutes. The impeller torque and the
product temperature were monitored to determine the end point of granulation. The
granules were sieved through a suitable mesh and dried in an oven at 60 °C to a final
moisture content of 1.5–2 %, m/m (determined using a Sartorius moisture balance, Ger-
many).
Preparation of tablets
Granules were mixed with required quantities of superdisintegrant (as required)
and lubricant and blended for 5 minutes in a V-cone blender (8 rpm) to form a homoge-
neous powder mix and compressed using suitable punches (for 600 mg 19/9 mm cap-
sule shaped standard concave, for 200 mg 11-mm round concave and for 100 mg 8-mm
round concave punch set) on a 16-station rotary tablet press (Cadmach model CMD4, In-
dia). Advanced Instrumentation Monitor (AIM) software (Metropolitan Computing Cor-
poration, USA) was used with the tablet press to determine the compression force re-
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quired to give tablets of approximately equal hardness for the various doses used in the
study. The formulae of the tablets prepared are shown in Table I.
Hardness and friability determination
The hardness of the prepared tablets was determined 24 hours after compression
using an Erweka hardness tester (Erweka TBH 310 MD, Germany), which also measures
the tablet diameter. Ten tablets were tested for hardness from each batch and the mean
and SD were calculated.
Pre-weighed 20 tablets were placed in a plastic chambered friabilator (Erweka TAR
200, Germany) attached to a motor revolving at a speed of 25 rpm for 4 min. The tablets
were then de-dusted, reweighed and percentage mass loss (friability) was calculated.
Disintegration time
Disintegration time of the prepared tablets was measured in 900 mL of purified wa-
ter at 37 °C, using an Erweka TAR series tester. Disintegration time of 12 individual tab-
lets was recorded.
Content uniformity
The prepared tablet formulations were assayed for drug content. Ten tablets were
randomly selected from each batch and pulverized to a fine powder. Weighed aliquots
containing an amount of powder equivalent to a single dose were taken in triplicate and
assayed for the drug content using HPLC (Waters Corp., MA, USA). Buffer (0.01 mol L–1
of ammonium acetate solution, pH adjusted to 7.5 using dilute ammonia) mixed with
acetonitrile (1:1) was used as the mobile phase at a flow rate of 1.5 mL min–1. C18 column
of 250 ´ 4.6 mm, 5 mm (BDS Hypersil) maintained at 25 °C was used for separation of the
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Table I. Composition of efavirenz tablets
Ingredient Mass (mg)
Efavirenz 600 200 100
Microcrystalline cellulose PH 101 225 68 34
Lactose 225 80 40
Plasdone K29/32 36 12 6
SLS 30 12 6
Disintegranta,b 60 20 10
Magnesium stearate 12 4 2
Aerosil 12 4 2
Total tablet mass 1200 400 200
a Disintegrants: CCS – crosscarmellose solidum, SSG – solidum starch glycollate, CP – crosspovidone.
b Disintegrants were incorporated intra (IG), extra (EG) or 50 % of disintegrant intra and 50 % disintegrant
extragranularly.
drug. The injected volume was 20 mL and the eluate was detected for EFV using a UV
detector (Model 8453 Agilent Technologies, Germany) at 252 nm. The total run time was
20 minutes.
Differential scanning calorimetry (DSC)
DSC was used to characterize the thermal properties of the drug in the compressed
tablet using appropriate controls. The DSC thermograms were recorded using a differ-
ential scanning calorimeter (Q 1000, TA Instruments, USA). Ultra-high pure nitrogen
was used at a flow rate 50 mL min–1. Samples were analyzed in crimped aluminum pans
and heated from 20–200 °C at a linear heating rate of 20 °C min–1.
In vitro dissolution studies
Dissolution studies of the prepared tablets were carried out using a USP apparatus
II (Vankel VK, USA). Dissolution was performed in 1000 mL of water with 2 % sodium
lauryl sulfate (SLS) (FDA recommended medium, 5) and with 1000 mL water with 0.2 %
SLS (discriminatory medium), at 37 ± 0.5 °C and at 50 rpm. An auto sampler, coupled to
the dissolution apparatus was programmed to withdraw and replace 10 mL of the disso-
lution medium at 5, 10, 15, 30, 45 and 60 minutes. The withdrawn samples were ana-
lyzed for EFV content spectrophotometrically at 252 nm, after appropriate dilution with
the respective medium if required. The time required for 50 and 80 % of drug to be re-
leased (t50 and t80) was used to compare the dissolution results. The t50 and t80 were de-
termined by fitting the dissolution data to a four parametric logistic model using the
Marquardt-Levenberg algorithm (Sigmaplot 9.0 SPSS Inc., Chicago, USA) (6):





log1 10 50[ ]
In this equation, y represents the cumulative % of drug released, x is the time in minutes,
min is the baseline of % drug released at time 0, max is the plateau of % drug released at
60 minutes, and the slope is the slope of the curve at transition center (EC50).
RESULTS AND DISCUSSION
Only a few reports on the three modes of addition of disintegrants are available. For
example, Gordon (7) demonstrated that EG addition was far superior to other modes of
incorporation in releasing the principal tablet component. Preetha et al. (8) showed that
the solubility of the main component may not be influential in determining the mode of
disintegrant incorporation, but the solubility and nature of the drug may be important
in selecting the disintegrant of choice.
Mass and thickness of the prepared tablets were within 1202.4 ± 21.2 mg and 3.54 ±
0.5 mm, respectively. Further, the hardness of the prepared tablets was maintained at
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120 ± 5 N and the friability was much lower than 1 %. All formulations demonstrated
good content uniformity, varying from 98.6 ± 0.1 to 102.2 ± 0.2 % (Table II).
All tablets disintegrated rapidly in the USP disintegration test. The disintegration
time was dependent on the type of disintegrant used. The disintegration times of 600 mg
tablets, where the disintegrants were added EG, IG or distributed equally between the
two phases, showed that tablets prepared with CP showed no difference in disintegra-
tion times, while the disintegration times increased for tablets containing CCS and SSG,
when these were added IG or distributed equally between the two phases (Table II). The
disintegration times of tablets containing CCS and SSG IG increased almost 1.5 times
compared to the respective disintegration time of the tablets containing these disinte-
grants, added EG.
In general, tablets containing CP as disintegrant disintegrated more rapidly com-
pared to tablets containing CCS and SSG. Out of the three disintegrants studied, SSG
showed longer disintegration time at all three dose levels of the EFV studied. SSG and
CCS generally swell rapidly and the extent of swelling of SSG is more than that of CCS,
which might have resulted in marginally slower disintegration time of tablets prepared
with SSG. This is in accord with earlier findings (9).
CP polymers are densely cross-linked homopolymers of N-vinyl-2-pyrrolidones.
Their porous particle morphology enables them to rapidly absorb liquids into the tablet
by capillary action and to generate rapid volume expansion and hydrostatic pressures
that result in tablet disintegration.
189
Y. V. Rajesh et al.: Impact of superdisintegrants on efavirenz release from tablet formulations, Acta Pharm. 60 (2010) 185–195.






600 mg EG 600 mg IG
600 mg
EG + IG
200 mg EG 100 mg EG
CCS
Hardness (N) 122.5  1.2 121.4  1.0 123.5  2.1 124.2  0.8 121.4  1.0
Friability (%) 0.14 0.18 0.16 0.11 0.10
Disintegration
time (min)
5.14 8.06 6.48 3.26 1.54
Content (%) 99.6 ± 0. 2 101.5 ± 0.2 100.4 ± 0.2 98.6 ± 0.1 100.7 ± 0.1
SSG
Hardness (N) 120.8  1.8 120.8  2.2 123.8  1.6 120.6  1.9 121.6  2.4
Friability (%) 0.17 0.20 0.18 0.14 0.15
Disintegration
time (min)
8.26 11.58 9.22 5.81 3.43
Content (%) 100.2 ± 0.1 101.5 ± 0.1 99.5 ± 0.1 98.7 ± 0.2 102.2 ± 0.2
CP
Hardness (N) 121.0  1.5 123.5  1.4 121.5  2.1 124.4  0.6 122.5  1.4
Friability (%) 0.11 0.1 0.13 0.09 0.07
Disintegration
time (min)
3.57 4.06 4.04 1.42 0.56
Content (%) 101.6 ± 0.2 99.3 ± 0.2 100.4 ± 0.1 98.6 ± 0.1 99.5 ± 0.1
For acronyms see Table I.
Visually, tablets formulated with CP could be seen to rapidly disintegrate into more
or less uniform fine particles, while tablets formulated with CCS and SSG appeared to
disintegrate much more slowly into more or less uniform coarser particles.
In vitro dissolution studies
In general, the recommended dissolution medium for in vitro dissolution testing can
be used for formulation development and it is typically non-discriminatory between for-
mulation ingredients. Drug release of a poorly soluble drug like EFV, as used in the
study, is usually driven more by the medium than by the formulation ingredients. Dis-
criminatory dissolution profiles are highly desirable for distinguishing between pro-
ducts showing differences in pharmaceutical attributes (formulation or manufacturing
process differences) as is the case in the present study, wherein the difference in formula-
tion was only with respect to the disintegrant used (10–13).
Figure 1 shows the dissolution profile of 600-mg EFV tablet in water containing dif-
ferent concentrations of SLS containing CP as disintegrant. The dissolution studies in the
recommended medium showed that tablets with CP as disintegrant released the drug
faster than the other disintegrants (Table III), and hence it was used for determining a
discriminatory dissolution medium. This is evidenced by the t50 and t80 value. To arrive
at a discriminatory medium, the approach adopted was to progressively decrease the
concentration of SLS used. From the dissolution profile shown in Fig. 1, it was decided
to use water with 0.2 % SLS as the discriminatory medium. The concentrations above
0.2 % failed to show much difference in the rate and extent of drug release while concen-
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Table III. t50 and t80 of efavirenz tablet formulations
Superdisintegrant
Drug + superdisintegrant
600 mg EG 600 mg IG
600 mg
EG + IG
200 mg EG 100 mg EG
CCS
t50 (minutes)
RM 17.4 30.07 25.68 10.8 8.16
DM 29.53 ND ND 43.68 38.28
t80 (minutes)
RM 44.27 NA 49.56 28.37 18.13
DM NA ND ND NA 58.26
SSG
t50 (minutes)
RM 27.66 39.54 27.54 19.17 16.96
DM NA ND ND NA NA
t80 (minutes)
RM NA NA NA 52.02 35.37
DM NA ND ND NA NA
CP
t50 (minutes)
RM 9.62 8.53 10.8 9.6 10.09
DM 22.21 ND ND 19.72 18.69
t80 (minutes)
RM 27.54 29.82 28.23 25.21 20.85
DM NA ND ND 56.75 45.71
NA – not able to achieve desired % of drug release; ND – not done; RM – FDA recommended dissolution me-
dium; DM – discriminatory in-house medium.
For acronyms see Table I.
tration of SLS below 0.2 %, i.e., 0.1 %, failed to achieve any meaningful release since the
amount of drug dissolved was less than 40 %.
The dissolution profile of 600-mg EFV tablets prepared with different superdisin-
tegrants in the recommended medium and in the discriminatory medium is shown in
Figs. 2 a and b. The results show that the tablets prepared with CP showed faster disso-
lution than the corresponding tablets prepared with CCS or SSG, in both media, as also
evidenced by the t50 and t80 values (Table III). The results clearly demonstrate the supe-
riority of CP to enhance the release of the drug even in the discriminatory medium. The
concentration of SLS used was just below the critical micelle concentration of SLS, which
is 0.25 %, m/V (14) and shows that the choice of superdisintegrant has a significant im-
pact on drug dissolution. However, a similar trend was observed for tablets, with lower
doses; the difference was not very apparent between the tablets containing CCS and CP
as disintegrants, especially at the 100-mg dose level. The solubility of EFV, being a
poorly soluble drug, is expected to be indirectly proportional to the concentration of the
drug.
In an earlier study (13) EFV capsules with rapid dissolution were formulated using
SSG as superdisintegrant. However, the concentration of SSG used in this study was
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Fig. 1. Effect of different concen-
trations of sodium lauryl sulfate
(SLS) on EFV release from 600-mg
tablets containing crosspovidone
as disintegrant. Values represent

















































Fig. 2. Dissolution of efavirenz from 600-mg tablets prepared using different superdisintegrants in:
a) 1000 mL of water with 2 % solidum lauryl sulfate (SLS) (FDA recommended medium), and b)
1000 mL of water with 0.2 % SLS (discriminatory in-house medium). Values represent mean ± SD (n
= 6). For acronyms see Table I.
high (20 % or more) and the study did not compare capsules prepared with similar con-
centrations of other disintegrants such as CCS and CP. In the present study, we demon-
strated that among the three disintegrants studied, CP was able to increase the dissolu-
tion rate of EFV from the tablet formulation at 5 % level, which was significantly less
than in the reported study.
The dissolution profiles of 600-mg EFV tablets prepared by varying the mode of in-
corporation of the different disintegrants are shown in Fig. 3a-c. The overall release of
EFV from tablets containing SSG added EG was much lower than that of the tablets con-
taining CP as disintegrant, as discussed earlier. Incorporation of CCS and SSG IG see-
med to retard the drug release. The results correlated well with the disintegration times
of tablets, as discussed earlier.
Fig. 4 shows the thermograms recorded for pure EFV, lactose, blend of EFV and lac-
tose at the same ratio as in the tablet and the EFV tablets containing different disinte-
grants. It was observed that the characteristic endotherms for both EFV and lactose sho-
wed a slight shift in the thermogram of the blend. This could be attributed to the fact
that lactose may act as an impurity to EFV. Thermograms of the tablets showed a slight
reduction in the endothermic transition of the drug with respect to the endothermic
transition of EFV observed in the thermogram of the blend. In order to ascertain
whether the observed reduction in peak intensity was caused by loss of crystallinity of
the drug or its dilution (due to the presence of other tablet excipients), % crystallinity
was determined using the formula:
% crystallinity = 100 ´ DHs / (DHc ´ C)
DHs is the enthalpy of fusion of EFV in EFV/lactose blend, DHc is the enthalpy of fusion
of EFV in crushed tablet. The enthalpy of fusion of the drug in the lactose-EFV blend
was used for calculation of % crystallinity of the drug in the tablet instead of enthalpy of
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Fig. 3. Effect of the mode of addition of di-
sintegrants on release of EFV from 600-mg
tablets prepared using different superdisin-
tegrants in 1000 mL of water with 2 % so-
dium lauryl sulfate (recommended medi-
um). Values represent mean ± SD (n = 6).
For acronyms see Table I.
fusion of pure drug since this would take into account the effect of lactose on the solid
state characteristics of EFV. The % crystallinity of the drug in the prepared tablets was
between 90 and 94 %, suggesting that the other tablet excipients and the process of pre-
paring the tablets did not influence the solid state characteristics of the drug. Hence, it
could be deduced that the improvement observed in the dissolution was not due to the
possible amorphization of the drug but only to the excipients used in the tablet. The
only excipient that was different in the tablets prepared was the disintegrant.
CONCLUSIONS
The comprehensive study conducted to evaluate the impact of different
superdisintegrants on the dissolution rates of EFV from tablet formulations containing
different doses of the drug showed that CP provided the fastest rate of dissolution both
in the USFDA recommended and the discriminatory (in-house developed) media. Fur-
ther, the mode of disintegrant addition did not affect the drug release when CP was
used as disintegrant, unlike CCS or SSG, wherein IG addition decreased the drug release
appreciably in both cases.
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S A @ E T A K
Utjecaj superdezintegratora na osloba|anje efavirenca iz tableta
YELCHURI VIJAYA RAJESH, JAGDISH BALASUBRAMANIAM, KODURI BINDU,
RAMACHANDRAN SRIDEVI, MAROJU SWETHA i VINAY UMESH RAO
U radu je opisana priprava tableta s razli~itim dozama efavirenca (EFV) metodom
vla`ne granulacije. Za tabletiranje kori{teni su razli~iti superdezintegratori, poput na-
trijeve kroskarmeloze (CCS), natrijeva {krobnog glikolata (SSG) i krospovidona (CP),
kako bi se procijenio utjecaj vrste i na~ina dodavanja dezintegratora na osloba|anje EFV
in vitro. U tu svrhu pripravljene su tablete sa 600 mg EFV, a dezintegrator je dodavan
ekstragranularno (EG), intragranularno (IG) ili je bio podjednako raspr{en (IG i EG). In
vitro osloba|anje pra}eno je u preporu~enom mediju i mediju izra|enom u na{em la-
boratoriju kako bi se uo~ila razlika izme|u formulacija. Vrijednosti t50 i t80 ukazuju na to
da je osloba|anje lijeka br`e iz formulacija koje sadr`e CP u oba medija. Na~in dodava-
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nja CP nema utjecaj na osloba|anje lijeka, osim za CCS, gdje se ekstragranularno doda-
vanje pokazalo povoljnijim.
Klju~ne rije~i: efavirenc, superdezintegratori, granulacija
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